Zuo C, Wang G, Yang K, Che X, Meng Y, Zhang K
Department of Urology, Peking University First Hospital, Beijing 100034, China.
Department of Urology, Beijing Miyun District Hospital, Beijing 101500, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Aug 18;57(4):711-716. doi: 10.19723/j.issn.1671-167X.2025.04.013.
To evaluate the effectiveness and safety of thulium fiber laser enucleation of the prostate (ThuFLEP) in the treatment of oversized (>200 mL) prostate.
Clinical data of 475 benign prostatic hyperplasia (BPH) patients operated by the same urologist at Peking University First Hospital from January 2022 to May 2024 were retrospectively analyzed, all of whom were treated with thulium fiber laser, and the patients were divided into three groups according to the total volume of the prostate (TPV): group A (TPV < 100 mL), group B (100 mL≤TPV < 200 mL), and group C (TPV≥200 mL). The age of the patients in the three groups [(69.38±7.79) years, (69.64±8.69) years, (70.32±7.44) years], International Prostate Symptom Score (IPSS) [(22.7±1.9), (22.8±2.7), (25.8±3.7)], and the maximum urinary flow rate (Qmax) [(7.9±2.7) mL/s, (9.3±4.3) mL/s, (9.9±3.3) mL/s] were not statistically significant (>0.05). The prostate volume in the three groups [(103.49±46.19) mL, (75.73±30.69) mL, (273.49±49.19) mL] and prostate specific antigen (PSA) [3.52 (1.05, 8.76) μg/L, 6.78 (1.61, 7.45) μg/L, 8.52 (5.05, 12.76) μg/L] were statistically significant ( < 0.05).
All surgeries were successfully completed. The dif-ferences in enucleation time [30.0 (21.2, 44.5) min, 41.6 (31.2, 52.5) min, 45.1 (35.2, 50.0) min] and hospitalization time [(6.06±1.21) d, (6.15±1.50) d, (7.71±1.74) d] among the three groups were not statistically significant (>0.05); and the differences in the postoperative indwelling catheter time [(4.0±1.4) d, (4.0±1.3) d, (6.6±1.1) d], operative time [61 (42, 89) min, 82 (62, 105) min, 115 (96, 142) min], enucleation efficiency [1.29 (0.71, 1.56) g/min, 1.67 (1.23, 2.15) g/min, 2.74 (2.20, 3.34) g/min], and hemoglobin drop values [12 (7, 19) g/L, 17 (11, 24) g/L, 27 (19, 35) g/L] were statistically different ( < 0.05). Linear regression ana-lysis was used to show a strong positive linear correlation between enucleation efficiency and enucleation weight (=0.880, < 0.001), and the enucleation efficiency increased with the increase of prostate volume. The differences in IPSS [(6.6±1.7), (6.2±1.4), (4.6±1.1)] and Qmax [(18.9±3.1) mL/s, (16.8±3.8) mL/s, (22.9±7.1) mL/s] were not statistically significant among the three groups (>0.05), and the differences in IPSS and Qmax were statistically significant compared with those before surgery. The differences were statistically significant in preoperative comparisons, but the postoperative urinary flow rate of group C increased significantly more than the remaining two groups in terms of Qmax ( < 0.05). The patients in the three groups were followed up for 3 months, and post-operative complications were categorized into Clavien-Dindo Ⅰ (urinary retention, persistent hematu-ria), Clavien-Dindo Ⅱ (glandular remnants, urinary tract infection, blood transfusion) and Clavien-Dindo Ⅲ (urethral stenosis, contracture of the bladder neck, and reoperation for hemorrhage) based on the Clavien-Dindo Complications System score, the incidence of Clavien-Dindo in the three groups was 5.2% (13 cases), 6.7% (12 cases) and 12.1% (7 cases), respectively, with statistically significant differences ( < 0.05); among them, there were statistically significant differences in urinary infection, blood transfusion and bleeding reoperation ( < 0.05), and there was no statistically significant difference in the remaining complications (>0.05).
The risk of blood transfusion and re-hemostasis increases with larger prostate volume, the efficiency of enucleation increases with the increase of prostate vo-lume, and thulium fiber laser prostate enucleation is safe and effective in the treatment of large-volume BPH.
评估铥激光前列腺剜除术(ThuFLEP)治疗超大体积(>200 mL)前列腺的有效性和安全性。
回顾性分析2022年1月至2024年5月在北京大学第一医院由同一位泌尿外科医生手术的475例良性前列腺增生(BPH)患者的临床资料,所有患者均接受铥激光治疗,并根据前列腺总体积(TPV)将患者分为三组:A组(TPV<100 mL)、B组(100 mL≤TPV<200 mL)和C组(TPV≥200 mL)。三组患者的年龄[(69.38±7.79)岁、(69.64±8.69)岁、(70.32±7.44)岁]、国际前列腺症状评分(IPSS)[(22.7±1.9)、(22.8±2.7)、(25.8±3.7)]和最大尿流率(Qmax)[(7.9±2.7)mL/s、(9.3±4.3)mL/s、(9.9±3.3)mL/s]差异无统计学意义(>0.05)。三组患者的前列腺体积[(103.49±46.19)mL、(75.73±30.69)mL、(273.49±49.19)mL]和前列腺特异性抗原(PSA)[3.52(1.05,8.76)μg/L、6.78(1.61,7.45)μg/L、8.52(5.05,12.76)μg/L]差异有统计学意义(<0.05)。
所有手术均顺利完成。三组患者的剜除时间[30.0(21.2,44.5)分钟、41.6(31.2,52.5)分钟及45.1(35.2,50.0)分钟]和住院时间[(6.06±1.2)天、(6.15±1.50)天、(7.71±1.74)天]差异无统计学意义(>0.05);术后留置导尿管时间[(4.0±1.4)天、(4.0±1.3)天、(6.6±1.1)天]、手术时间[61(42,89)分钟、82(62,105)分钟、115(96,142)分钟]、剜除效率[1.29(0.71,1.56)g/分钟、1.67(1.23,2.15)g/分钟、2.74(2.20,3.34)g/分钟]及血红蛋白下降值[12(7,19)g/L、17(11,24)g/L、27(19,35)g/L]差异有统计学意义(<0.05)。线性回归分析显示,剜除效率与剜除重量之间存在强正线性相关(r=0.880,P<0.001),且剜除效率随前列腺体积增加而提高。三组患者的IPSS[(6.6±1.7)、(6.2±1.4)、(4.6±1.1)]和Qmax[(18.9±3.1)mL/s、(16.8±3.8)mL/s、(22.9±7.1)mL/s]差异无统计学意义(>0.05),且与术前相比,IPSS和Qmax差异有统计学意义。术前比较差异有统计学意义,但C组术后尿流率在Qmax方面较其余两组显著增加(P<0.05)。三组患者随访3个月,根据Clavien-Dindo并发症系统评分将术后并发症分为Clavien-DindoⅠ级(尿潴留、持续性血尿)、Clavien-DindoⅡ级(腺体残留、尿路感染、输血)和Clavien-DindoⅢ级(尿道狭窄、膀胱颈挛缩、出血再次手术),三组Clavien-Dindo发生率分别为5.2%(13例)、6.7%(12例)和12.1%(7例),差异有统计学意义(P<0.05);其中,尿路感染、输血及出血再次手术差异有统计学意义(P<0.05),其余并发症差异无统计学意义(>0.05)。
随着前列腺体积增大,输血和再次止血风险增加,剜除效率随前列腺体积增加而提高,铥激光前列腺剜除术治疗大体积BPH安全有效。